Royalty Report: Drugs, Therapeutic, Biotechnology – Collection: 3499

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Biotechnology
  • Disease
  • Technical Know How
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3499

License Grant
A Swiss licensee and an Irish licensor announced a worldwide, exclusive collaboration to develop and commercialize antibodies that target alpha-synuclein, including PRX002. The license is granting rights to develop, make, have made, use, sell, offer to sell, import, and export the Licensed Products. Licensor will retain certain rights to conduct development of the Licensed Products and an option to co-promote PRX002.

Also as part of the agreement, the companies will initiate a research collaboration focused on optimizing early stage antibodies targeting alpha-synuclein including incorporation of licensee's proprietary Brain Shuttleâ„¢ technology to increase delivery of therapeutic antibodies to the brain.

License Property
PRX002 is a monoclonal antibody for the treatment of Parkinsons disease, which is currently in preclinical development and is expected to enter Phase 1 clinical trials in patients with Parkinsons disease in 2014.  

Synuclein proteins are a family of charged proteins found throughout the body. One protein from this family, alpha-synuclein, is found extensively in neurons and is a major component of pathological inclusions that characterize several neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, neurodegeneration with brain iron accumulation type 1, and multiple system atrophy, which collectively are termed synucleinopathies.

Field of Use
The rights granted apply to the medical industry.  Also as part of the agreement, the companies will initiate a research collaboration focused on optimizing early stage antibodies targeting alpha-synuclein including incorporation of licensee's proprietary Brain Shuttleâ„¢ technology to increase delivery of therapeutic antibodies to the brain.

IPSCIO Record ID: 224822

License Grant
The Licensor has granted the Irish Licensee an exclusive, sublicensable, worldwide license for its joint ownership interest in certain patents jointly owned with the Licensee. Those patents relate to the Licensees program targeting a-synuclein for the treatment of neurodegenerative disorders such as Parkinson’s disease.
License Property
The protein a-synuclein is found extensively in neurons and is a major component of pathological inclusions that characterize several neurodegenerative disorders, including Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy.
Field of Use
The Irish Licensee will generate revenues through development and commercialization.

IPSCIO Record ID: 26360

License Grant
Upon the effectiveness of the License Agreement, the Licensor will grant to the Licensee an exclusive, worldwide License to develop, make, have made, use, sell, offer to sell, import, and export the Licensed Products.
License Property
The Licensor entered into a License, Development, and Commercialization Agreement with the Licensee to develop and commercialize certain antibodies that target alpha-synuclein, including PRX002, the Licensor's monoclonal antibody for the treatment of Parkinsons disease.

The Licensor will retain certain rights to conduct development of the Licensed Products and an option to co-promote PRX002.

Thereafter, during the term of the License Agreement, the Licensor and the Licensee will work exclusively with each other to research and develop antibody products targeting alpha-synuclein.

A tiered, high single-digit to high double-digit royalties in the teens on ex-U.S. annual net sales, subject to certain adjustments. In the United States, the parties will share all development and commercialization.

Field of Use
After the filing of the investigational new drug application with the U.S. Food and Drug Administration for PRX002 by Licensor, the Licensee will be primarily responsible for developing, obtaining and maintaining regulatory approval for, and commercializing the Licensed Products.

The rights granted apply to the healthcare industry.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.